Pinealon vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by the St. Petersburg Institute of Bioregulation, designed to penetrate the blood-brain barrier and exert neuroprotective, neurogenic, and anti-aging effects by regulating pineal gland and brain cell function.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- Short (peptides rapidly degraded), but epigenetic/gene regulatory effects persist
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, Oral, Intranasal
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10 mg (oral) or 50–100 mcg (SC)
- 10 mg per day
- Frequency
- Once daily for 10 days
- Daily for 10–30 days
- Key Benefits
- Neuroprotection against oxidative stress and hypoxia
- Promotes neuronal regeneration and repair
- Improves memory and cognitive function
- Enhances sleep quality via melatonin regulation
- Anti-aging effects on brain cells
- May slow cognitive decline in neurodegeneration
- Improves cerebrovascular circulation
- Reduces neuroinflammation
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Excellent safety profile in clinical use
- Rare: mild drowsiness
- Transient mild headache at initiation
- Injection site reaction (SC)
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —